<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837640</url>
  </required_header>
  <id_info>
    <org_study_id>RP DOPA</org_study_id>
    <nct_id>NCT02837640</nct_id>
  </id_info>
  <brief_title>Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa</brief_title>
  <official_title>The Effect of L-Dopa on the Progression of Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beirut Eye Specialist Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beirut Eye Specialist Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of L-Dopa on the progression of retinitis
      pigmentosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis pigmentosa is a group of progressive hereditary diseases that diffusely affects the
      functioning of photoreceptors and the pigment epithelium. It may be speculated that a
      protective effect on the pigment epithelium, as it is supposed for L-Dopa, can slow the
      progression of the disease or even lead to an, at least transient, improvement of visual
      functions. To evaluate the effect of L-Dopa on retinitis pigmentosa progression, visual
      acuity, electroretinogram and visual field will be preformed regularly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Electroretinogram</measure>
    <time_frame>Baseline, 1 year, 2 years, 5 years</time_frame>
    <description>the electric response to light stimuli of the retina, in millivolt, will be measured. The electroretinogram shows a-waves (elicit information about the function of the photoreceptors) and b-waves (elicit information about other neurosensory structure of the retina)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity</measure>
    <time_frame>Baseline, 6 months, 1 year, 2 years, 5 years</time_frame>
    <description>Visual acuity will be measured using Snellen chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Field</measure>
    <time_frame>Baseline, 1 year, 2 years, 5 years</time_frame>
    <description>Using 24-2 Humphrey Visual Field Analyzer, the progress in visual field defect will be measured, comparing mean deviation (dB) and pattern standard deviation (dB)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.
patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa-carbidopa</intervention_name>
    <description>sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Sinemet 200/50</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All confirmed cases of retinitis pigmentosa

          -  VA of 20/400 or better

        Exclusion Criteria:

          -  Advanced stages of retinitis pigmentosa with poor best corrected visual acuity (less
             than 20/400)

          -  co-existing eye morbidities interfering with retinitis pigmentosa (glaucoma, retinal
             detachment...)

          -  Flat electroretinogram

          -  Intolerance or counterindication to drug

          -  Unability for long-term follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias F. Jarade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beirut Eye Specialist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elias F. Jarade, MD</last_name>
    <phone>+9613549297</phone>
    <email>ejarade@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beirut Eye Specialist Hospital</last_name>
    <phone>+961 1 423111</phone>
    <phone_ext>0</phone_ext>
    <email>info@besh.com.lb</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beirut Eye Specialist Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>116-5311</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Cherfan, MD, Prof</last_name>
      <phone>+961 1 423111</phone>
      <phone_ext>160</phone_ext>
      <email>georgecherfan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <reference>
    <citation>Brilliant MH, Vaziri K, Connor TB Jr, Schwartz SG, Carroll JJ, McCarty CA, Schrodi SJ, Hebbring SJ, Kishor KS, Flynn HW Jr, Moshfeghi AA, Moshfeghi DM, Fini ME, McKay BS. Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. Am J Med. 2016 Mar;129(3):292-8. doi: 10.1016/j.amjmed.2015.10.015. Epub 2015 Oct 30.</citation>
    <PMID>26524704</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Levodopa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant date will not be shared at the moment being, since it is not of value unless it is thoroughly analysed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

